The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (Pts) with advanced gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis.
 
Yoshiaki Nakamura
Research Funding - Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Hiroya Taniguchi
Honoraria - Bayer; Chugai Pharma; Lilly Japan; Merck Serono; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Hideaki Bando
Honoraria - Chugai Pharma; Lilly Japan; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - AstraZeneca; Sysmex
 
Ken Kato
Honoraria - Bristol-Myers Squibb; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - BeiGene; MSD; Oncolys BioPharma; Oncolys BioPharma; Ono Pharmaceutical
Research Funding - Beigene (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)
 
Taito Esaki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Merck Serono; MSD; Nihonkayaku; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Shiseido; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; Daiichi Sankyo; Eisai; Incyte; IQvia; Mediscience Planning; Merck Sharp & Dohme; NanoCarrier; Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon; Sysmex; Taiho Pharmaceutical; Yakult Honsha
 
Naoki Takahashi
No Relationships to Disclose
 
Makoto Ueno
Honoraria - AstraZeneca; Merck Serono; Nipro Corporation; Shire; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Shire
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Shire (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Yoshinori Kagawa
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck; MSD; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
 
Tomohiro Nishina
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Nihonkayaku; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Takeshi Kato
Honoraria - Bayer; Chugai Pharma; Lilly; Takeda; Yakult Honsha
Research Funding - Chugai Pharma
 
Yoshiyuki Yamamoto
Honoraria - Asahi Kasei; Chugai Pharma; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical
 
Junji Furuse
Honoraria - Abbvie; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD; Nihon Servier; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Sawai Pharmaceutical Co; Shionogi; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Otsuka; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Takara Bio; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Tadamichi Denda
Speakers' Bureau - Chugai Pharma (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
Research Funding - MSD (Inst)
 
Hisato Kawakami
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst)
 
Eiji Oki
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Merck; Nippon Kayaku; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Merck Serono (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst)
 
Takayuki Yoshino
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst)
 
Atsushi Ohtsu
Employment - Celgene (I)
Honoraria - Chugai Pharma; Ono Yakuhin; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb